Fast and accurate high resolution genotyping of complex immune regions is critical to improving transplant outcomes and understanding disease associations.
Scisco Genetics is dedicated to:
Providing high quality sequence-based typing solutions and services for complex immune gene systems, including HLA and KIR.
Enabling Next Generation Sequencing technology in clinical laboratories that support transplant programs.
Continuous quality improvement in sequencing technology and software analysis tools.
We are a Seattle-based company established in 2006 by Dr. Dan Geraghty, a member of the Fred Hutchinson Cancer Research Center, to build on his research in HLA and KIR immunogenetics. We are accredited by the American Society for Histocompatibility and Immunogenetics (ASHI)—the leading accreditation program for histocompatibility testing laboratories, the Clinical Laboratory Improvement Amendments (CLIA) program, and the Washington State Department of Health.
Scisco Genetics Inc. is committed to providing the highest possible standard of testing to our clients. Therefore, we have implemented a quality assurance program to ensure continuous improvement in our performance and accurate and reliable test results for our customers. Given good quality DNA samples, our quality metric is to obtain 100% accuracy in typing.
Our quality assurance program has been assessed and approved by the American Society for Histocompatibility and Immunogenetics (ASHI) and the Clinical Laboratory Improvements Amendments (CLIA).